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Inﬂammation can be either beneﬁcial or detrimental to the liver,
depending on multiple factors. Mild (i.e., limited in intensity and
destined to resolve) inﬂammatory responses have indeed beenJournal of Hepatology 20
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voltage-dependent anion channel; UPR, unfolded protein response.shown to exert consistent hepatoprotective effects, contributing
to tissue repair and promoting the re-establishment of homeosta-
sis. Conversely, excessive (i.e., disproportionate in intensity and
permanent) inﬂammation may induce a massive loss of hepato-
cytes and hence exacerbate the severity of various hepatic condi-
tions, including ischemia-reperfusion injury, systemic metabolic
alterations (e.g., obesity, diabetes, non-alcoholic fatty liver disor-
ders), alcoholic hepatitis, intoxication by xenobiotics and infec-
tion, de facto being associated with irreversible liver damage,
ﬁbrosis, and carcinogenesis. Both liver-resident cells (e.g., Kupffer
cells, hepatic stellate cells, sinusoidal endothelial cells) and cells
that are recruited in response to injury (e.g., monocytes, macro-
phages, dendritic cells, natural killer cells) emit pro-inﬂamma-
tory signals including – but not limited to – cytokines,
chemokines, lipid messengers, and reactive oxygen species that
contribute to the apoptotic or necrotic demise of hepatocytes.
In turn, dying hepatocytes release damage-associated molecular
patterns that-upon binding to evolutionary conserved pattern
recognition receptors-activate cells of the innate immune system
to further stimulate inﬂammatory responses, hence establishing
a highly hepatotoxic feedforward cycle of inﬂammation and cell
death. In this review, we discuss the cellular and molecular
mechanisms that account for the most deleterious effect of hepa-
tic inﬂammation at the cellular level, that is, the initiation of a
massive cell death response among hepatocytes.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V.
Introduction
Hepatic inﬂammation, which accompanies the majority of acute
and chronic liver disorders, is a complex process that originates
in response to a variety of stress conditions [1]. As in most other
organs, hepatic inﬂammation is put in place to protect hepato-
cytes from injury, to favor the repair of tissue damage, and to pro-
mote the re-establishment of homeostasis, de facto exerting
consistent hepatoprotective effects. However, inﬂammatory
responses that are too intense or fail to resolve (i.e., they become
chronic) are near-to-invariably accompanied by a massive loss of
hepatocytes and hence cause an irreversible damage to the liver
parenchyma (Supplementary Discussion) [2]. As myoﬁbroblasts
originating from hepatic stem cells take over and replace dead
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hepatocytes, unresolved inﬂammation can stimulate a ﬁbrotic/
cirrhotic response characterized by an irreversible decline in liver
functions [3]. Alternatively, owing to the fact that hepatocytes are
endowed with a consistent replicative potential and attempt at
reconstituting the dead parenchyma (which explains the clinical
success of the ‘‘split-liver’’ transplantation, in which two recipi-
ents received one half of the organ from a single donor) [4],
chronic inﬂammation signiﬁcantly increases the risk for hepatic
carcinogenesis [5]. Besides these two end-stage conditions, dys-
regulated inﬂammatory responses have been associated with
most (if not all) hepatotoxic insults, including (i) ischemia/reper-
fusion (IR) injuries; (ii) alcohol overconsumption; (iii) intoxica-
tions by xenobiotics or heavy metals (e.g., Cu2+, Hg2+); (iv)
bacterial, viral and parasitic infections; as well as (v) systemic
metabolic conditions, such as non-alcoholic fatty liver disease
(NAFLD), non-alcoholic steatohepatitis (NASH), obesity, diabetes,
and the metabolic syndrome [6]. Importantly, many distinct
liver-resident cells, circulating cells that are speciﬁcally recruited
to the hepatic parenchyma in response to stress and a large panel
of bioactive molecules, encompassing cytokines, chemokines,
lipid messengers and highly diffusible pro-oxidants, have been
implicated in hepatic inﬂammation [1].Key Points
• While mild inflammatory responses are beneficial to
the liver as they favor the re-establishment of tissue
homeostasis, excessive or chronic inflammation not
only aggravates liver injury as triggered by a wide array
of hepatotoxic insults, but also promotes fibrosis and
hepatic carcinogenesis
• When cell-intrinsic adaptive responses fail, hepatocytes
succumb to extracellular or intracellular stress 
conditions by undergoing apoptosis, a genetically-
controlled cell death mode that can be executed via
either of two signal transduction cascades, or necrosis,
which also can occur in a regulated fashion
• Prominent signals leading to the massive demise of
hepatocytes include TNFα, the overgeneration of ROS,
as well as the accumulation of misfolded proteins
in the endoplasmic reticulum. All these stimuli also
mediate robust pro-inflammatory effects, for instance
by promoting the activation of NF-kB or the NLRP3
inflammasome
• Multiple lipids including prostaglandins, leukotrienes,
ceramides, and free fatty acids have been involved in
the loss of liver parenchyma as induced by a plethora
of hepatotoxic stimuli. Lipotoxicity often proceeds
via stimulus-specific signaling pathways, yet almost
invariably is associated with inflammatory responses
• Dying hepatocytes emit a wide array of DAMPs,
including ATP, HMGB1, and nuclear DNA, which de
facto link cell death to the elicitation and progressive
aggravation of a vicious hepatotoxic inflammatory
response. Hepatic inflammation is kept under control
by senescence, which is specifically perceived and
eliminated by NK cells, and autophagy, which limit the
production of ROS as well as the release of DAMPs
584 Journal of Hepatology 201Most hepatic disorders are characterized by a profound mito-
chondrial dysfunction that can either drive the massive demise of
hepatocytes per se [7] or sensitize them to a variety of otherwise
non-lethal stress conditions, such as mild levels of hypoxia and/
or nutrient shortage [8]. Indeed, structural and functional altera-
tions of mitochondria have been reported to accumulate in livers
affected by IR injury, NASH, sepsis and Wilson’s disease [8–10].
This reﬂects, on the one hand the central role of hepatocytes in
the systemic metabolism of carbohydrates and lipids as well as
in the detoxiﬁcation of xenobiotics, and on the other hand the
critical functions of mitochondria at the hub of intracellular
metabolism, Ca2+ homeostasis, and cell death regulation [11].
Here we discuss the major deleterious consequence of liver
inﬂammation at the cellular level, that is the massive loss of func-
tional hepatic parenchyma, focusing on the cellular and molecu-
lar players involved in the initiation of this phenomenon.Cell death signals in the liver
Extrinsic and intrinsic apoptosis as well as regulated necrosis
(Fig. 1 and Supplementary Discussion) have been implicated in
the death of hepatocytes as triggered by a variety of hepatotoxic
insults such as viral and bacterial infections [12], metabolic disor-
ders [13], alcohol overconsumption [14], and intoxication by
xenobiotics [15].
Extracellular signals
Members of the tumor necrosis factor (TNF) protein superfamily,
including TNFa, CD95L (also known as FASL) and TNF-related
apoptosis-inducing ligand (TRAIL, ofﬁcial name TNFSF10) are
among the most prominent and best characterized inducers of
hepatocyte death. TNFa is produced in massive amounts by
hematopoietic cells exposed in vivo to living bacteria or lipopoly-
saccharide (LPS), de facto accounting for the fatal shock syndrome
that develops in these conditions (which includes a prominent
hepatic component) [16]. Of note, both the fulminant hepatotoxic
effects and the systemic lethality of TNFa are consistently
decreased in Ripk3/ mice [17], suggesting that regulated necro-
sis may play an important role in this setting, which has long
been considered as a pure apoptotic model.
TNFa is a highly pleiotropic cytokine, inducing biological
effects as diverse as cell proliferation, metabolic activation,
inﬂammatory responses and (apoptotic or necrotic) cell death
[18]. Thus, ligand-bound TNR receptor 1 (TNFR1) can elicit dis-
tinct signal transduction cascades, depending on several factors.
Generally, the stabilization of TNFR1 trimers by TNFa is rapidly
connected to the production of reactive oxygen species (ROS)
(via the plasma membrane NAPDH oxidase NOX1 as well as by
mitochondrial and cytosolic sources) [19] and to the activation
of NF-jB, orchestrating a pro-survival and pro-inﬂammatory
response [20]. In this setting, the NF-jB-mediated transactivation
of caspase-8 and FADD-like apoptosis regulator (CFLAR, best
known as c-FLIP) blocks cell death signals at the level of TNFR1
[21], hence allowing for the secretion of several pro-inﬂamma-
tory mediators including interleukin (IL)-6 and IL-8 [20]. Of note,
the acute phase protein IL-6 has been recently suggested to play a
prominent role in hepatic carcinogenesis as it activates signal
transducer and activator of transcription 3 (STAT3) [22]. Upon
internalization, the composition of the supramolecular com-
plexes assembled around TNFR1 changes, generally allowing for3 vol. 59 j 583–594
Fig. 2. Tumor necrosis factor signaling. Similar to CD95 ligand, tumor necrosis
factor a (TNFa) stabilizes pre-assembled TNFa receptor 1 (TNFR1) trimers, hence
allowing for the assembly of a membrane-proximal supramolecular complex
including (but not limited to) TRADD, FADD, receptor-interacting protein kinase 1
(RIPK1), as well as multiple cellular inhibitors of apoptosis proteins (cIAPs). In this
setting, RIPK1 gets rapidly ubiquitylated (by cIAPs and other ubiquitin ligases)
and hence triggers a signal transduction cascade that leads to the activation of
NF-jB, in turn resulting in the production of anti-apoptotic and pro-inﬂammatory
factors. Conversely, upon deubiquitylation (by cylindromatosis [CYLD] and other
enzymes), RIPK1 can recruit either caspase-8, therefore setting off the apoptotic
caspase cascade (see also Fig. 1), or, in caspase-incompetent settings, its homolog
RIPK3, resulting in the assembly of the ‘‘necrosome’’. In this latter case, both
RIPK1 and RIPK3 become phosphorylated and activate a mixed lineage kinase
domain-like (MLKL)-, phosphoglycerate mutase family member 5 (PGAM5)-,
mitochondrial fragmentation-dependent signaling pathway leading to necrosis.
CFLAR, caspase-8 and FADD-like apoptosis regulator; DRP1, dynamin-related
protein 1; IjB, inhibitor of NF-jB; IKK, IjB kinase; IL, interleukin; TAB, TAK1-
binding protein; TAK1, transforming growth factor b (TGFb)-associated kinase 1;
Ub, ubiquitin.
Fig. 1. Molecular mechanisms of apoptosis. Extrinsic apoptosis can lead to
either ligation of death receptors (e.g., CD95) or drop in the concentration of
dependence receptor (e.g., PTCH1) ligands below a speciﬁc threshold. In
particular, CD95 ligand (CD95L) stabilizes CD95 trimers, hence allowing for the
assembly of a plasma membrane-associated supramolecular complex that favors
the proximity-induced activation of caspase-8. In turn, active caspase-8 sets off
the executioner machinery of apoptosis by activating a proteolytic cascade
involving caspase-3, -6, and -7. Conversely, PTCH1 appears to mediate the
activation of executioner caspases via caspase-9-dependent signal transduction
cascade. Several intracellular stress conditions (e.g., DNA damage) are speciﬁcally
sensed by small members of the BCL-2 protein family (BH3-only proteins), which
activate mitochondrial outer membrane permeabilization (MOMP) by stimulating
the pore-forming activity of BAX and BAK. Alternatively, MOMP can be initiated at
the inner mitochondrial membrane by the unspeciﬁc opening of the ‘‘permeabil-
ity transition pore complex’’ (PTPC). Both these lethal cascades can be held in
check by anti-apoptotic BCL-2 proteins, which physically bind (hence inhibiting)
not only their pro-apoptotic counterparts but also various PTPC components.
MOMP is paralleled by the dissipation of the mitochondrial transmembrane
potential (Dwm) and results in the liberation of several mitochondrial proteins
such as cytochrome C (CYTC), which, together with the cytosolic adaptor APAF-1,
generates the caspase-9-activating platform known as ‘‘apoptosome’’; apoptosis-
inducing factor (AIF), which exerts caspase-independent pro-apoptotic functions
by mediating large-scale DNA fragmentation; and direct IAP-binding protein with
low pI (DIABLO), which physically antagonizes various inhibitor of apoptosis
proteins (IAPs). Thus, MOMP activates both caspase-dependent and caspase-
independent mechanisms of apoptosis. Of note, the caspase-8-mediated cleavage
of the BH3-only protein BID constitutes a major link between the extrinsic and
intrinsic apoptotic pathways. tBID, truncated BID.
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[23]. In this setting, caspase-8 inactivates receptor-interacting
protein kinase 1 (RIPK1) and RIPK3 [24] while setting off the
apoptotic caspase cascade, either alone or sustained by a mito-
chondrial ampliﬁcation loop mediated by truncated BID [25].
Conversely, in caspase-8-deﬁcient scenarios (e.g., in Casp8 knock-
out models or in the presence of caspase inhibitors), RIPK1 and
RIPK3 engage in physical interactions to form the ‘‘necrosome’’,
the signaling entity that leads to necroptosis [24] (Fig. 2).
Both Casp3/ and Bid/ mice are more resistant to lethal
hepatitis as triggered by anti-FAS agonistic antibodies than their
wild type littermates [26,27], suggesting that executioner caspas-Journal of Hepatology 201es and mitochondrial outer membrane permeabilization (MOMP)
are equally critical for the death of hepatocytes in this model.
Mice lacking mitogen-activated protein kinase 9 (Mapk9), best
known as c-JUN N-terminal kinase 2 (JNK2) are protected from
D-galactosamine/LPS- or D-galactosamine/TNFa-induced hepato-
toxicity [28], perhaps owing to a phosphorylation-dependent sta-
bilization of the anti-apoptotic protein MCL1 [28,29]. Along
similar lines, JNK1 has been shown to be required for TNFa-
induced fulminant hepatitis in vivo as it stimulates the ITCH-
dependent targeting of c-FLIP to proteasomal degradation [30].
Thus, distinct JNK isoforms, which can be directly activated upon
recruitment to the signaling complex assembled at the intracellu-
lar tails of TNFR1 or respond to ROS [19], play an important role
in the lethal signaling cascades triggered by TNFa and other hep-
atotoxic conditions (e.g., acetaminophen intoxication) [31].
Intracellular signals
As the liver is often exposed to biological and chemical stimuli
(see above), hepatocytes must rely on robust adaptive responses
for the maintenance of cellular and histological homeostasis. Key
processes in this context are the endoplasmic reticulum (ER)
stress response, autophagy, and the response to redox stress.
ER stress and autophagy: The intraluminal accumulation of
misfolded proteins signiﬁcantly affects ER functions, including
the regulation of Ca2+ homeostasis, and generally results in the
activation of a multipronged adaptive mechanism known as3 vol. 59 j 583–594 585
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unfolded-protein response (UPR) [32]. In mammalian cells, the
UPR is elicited by three distinct sensors: endoplasmic reticulum
to nucleus signaling 1 (ERN1, best known as inositol-requiring
enzyme 1a [IRE1a]), activating transcription factor 6 (ATF6)
and eukaryotic translation initiation factor 2a (eIF2a) kinase 3
(EIF2AK3, best known as PKR-related ER kinase [PERK]) [32].
Under physiological conditions, IRE1a, ATF6, and PERK engage
in inhibitory interactions with the ER-resident chaperone glu-
cose-regulated protein, 78 kDa (GRP78). Conversely, accumulat-
ing unfolded proteins competitively displace GRP78 from IRE1a,
ATF6 and PERK, leading to their activation and eventually to
the upregulation of mechanisms that attempt to re-establish
homeostasis, mainly involving (i) a general (but not complete)
translational arrest, (ii) the upregulation of factors that promote
protein folding and degradation, and (iii) the activation of
autophagy [32]. Autophagy is a homeostatic mechanism that is
critical both in baseline conditions, for the maintenance of intra-
cellular homeostasis [33], and during adaptive stress responses,
when it exerts major cytoprotective functions [34].
When the ER stress is mild and/or temporary, the combined
activation of the UPR and autophagy generally allows for the
recovery of homeostasis [35]. Conversely, protracted and/or
excessive signaling via ER stress sensors is associated with the
initiation of a mitochondrial pathway of apoptosis that involves,
among other proteins, the transcription factor C/EPB homologous
protein (CHOP), the protein phosphatase 1 (PP1) activator growth
arrest- and DNA damage-inducible gene 34 (GADD34), apoptosis
signal-regulating kinase 1 (ASK1), and JNK [36]. Interestingly, at
least part of the effects of JNK and ASK1 stem from their ability
to phosphorylate anti-apoptotic members of the BCL-2 family
[37], hence de-inhibiting Ca2+-modulatory (e.g., inositol 1,4,5-
trisphosphate receptor) [38], pro-autophagic (e.g., Beclin 1) [39]
and pro-apoptotic (e.g., BAX, BAK) factors [40]. Thus, JNK and
ASK1 appear to regulate a complex crosstalk between mecha-
nisms for the maintenance of intracellular homeostasis (such as
ER stress and autophagy) and the adaptive organismal response
for the removal of irremediably compromised, and hence poten-
tially dangerous cells (apoptosis).
A causal link between ER stress responses and the apoptotic
demise of hepatocytes has been established in a wide panel of
hepatic disorders, including viral infections [41], intoxication
with bacterial toxins [42], IR injuries [43], transplantation [44],
NASH and NAFLD [45]. Of note, the ER stress response is required
for the perception of cell death as immunogenic [46], and (no less
than) three distinct ER-resident chaperones, namely, calreticulin
(CRT), ERp57 and GP96, have been shown to exert immunostim-
ulatory effects [47,48]. It is therefore tempting to speculate, yet
remains to be formally demonstrated, that ER stress inhibitors
may be useful for preventing the unwarranted rejection of liver
allografts.
ROS: ROS, including anion peroxide and hydrogen peroxide,
are a normal side product of the mitochondrial respiratory chain
(mainly produced cat complex I and III), and, as they constitute
highly reactive and highly diffusible species, are involved in sev-
eral signal transduction cascades and adaptive stress responses
[11]. A quantitatively minor but functionally not less important
fraction of intracellular ROS is produced by plasma membrane,
cytosolic and reticular multicomponent NADPH oxidases (NOXs),
including NOX1, which participates in TNFR1-dependent NF-jB
activation, JNK activation, and necroptosis [49], by xanthine oxi-
dase, which catalyzes one step of purine catabolism [50], and by586 Journal of Hepatology 201enzymes of the cytochrome P450 family [51]. In the liver, the lat-
ter appear to account for a consistent proportion (if not for the
majority) of intracellular ROS production, even in the absence
of cytochrome P450 substrates [52].
In physiological settings, the cytotoxic potential of ROS is held
in check by a diversiﬁed battery of mitochondrial, cytosolic, and
peroxisomal antioxidant systems, including superoxide dismu-
tases, catalases, peroxiredoxins, thioredoxin, glutathione and
thiol-containing proteins [11]. In response to multiple stimuli,
however, ROS levels exceed the buffer capacity of these systems,
resulting ﬁrst in the activation of an adaptive response aimed at
the re-establishment of redox homeostasis coupled to an inﬂam-
matory response [53], and then in intracellular damage, progres-
sive mitochondrial dysfunction (paralleling the oxidation of
respiratory complexes and several other proteins involved in
mitochondrial metabolism), and cell death [7]. In particular,
intracellular ROS are known to affect the functions of key compo-
nents of the permeability transition pore complex (PTPC) includ-
ing voltage-dependent anion channel 1 (VDAC1) [54], adenine
nucleotide translocases (ANTs) [55] and subunits of the F1FO ATP-
ase [56], hence stimulating PTPC opening, MOMP and cell death
via intrinsic apoptosis. Of note, in some cell types including hepa-
tocytes, ROS activate ASK1 and their cytotoxic potential is largely
determined by its subcellular localization and interacting part-
ners [57].
The implication of ROS in the death of hepatocytes exposed to
toxic insults has been extensively documented, in vitro and
in vivo. Thus, redox stress has been shown to constitute an etio-
logical determinant of hepatotoxicity during IR [58,59], viral
infection [60], endotoxemia [61] ethanol intoxication [62] and
NASH [63], to mention a few examples. Conversely, ROS appear
to protect cirrhotic hepatocytes from transforming growth factor
b (TGFb)-induced apoptosis [64], and to be (at least partially)
responsible for the beneﬁcial effects of (hepatic) ischemic pre-
conditioning on hepatic and renal IR [65,66]. Finally, even in
the absence of overt cell death, ROS-dependent alterations of
mitochondrial metabolism in the liver have been associated with
multiple metabolic conditions, including insulin resistance [67].
NO and RNS: Similar to ROS, nitric oxide (NO) and reactive
nitrogen species (RNS) exert a large spectrum of biological effects
including (but not limited to) the stimulation of cell growth and
tissue regeneration, the control of vascular functions, and the
induction of cell death [68]. The major intracellular source of
NO is represented by NO synthases (NOS), which catalyze the
NAPDH- and O2-assisted conversion of L-arginine into citrulline
and NO [69]. However, whereas the endothelial NOS (eNOS) is
constitutively active and mainly mediates the beneﬁcial effects
of NO on vasculature, its inducible counterpart (iNOS) is upregu-
lated in response to stress, catalyzing intense (and hence poten-
tially dangerous) waves of NO production [69]. At the cellular
level, excess NO and RNS resemble ROS in their capacity to impair
energetic metabolism as they covalently modify a large panel of
proteins including mitochondrial complex IV [70] and ANT [71]
(both involved in mitochondrial respiration) as well as glyceral-
dehyde-3-phosphate dehydrogenase (GAPH) (a glycolytic
enzyme) [72], hence favoring the opening of the PTPC and cell
death.
In line with these considerations, NO and RNS have been
ascribed both hepatoprotective and hepatotoxic effects. For
instance, NO has been suggested to participate in liver
regeneration [73] and to protect hepatocytes from cell death at3 vol. 59 j 583–594
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reperfusion [74], but also to account (at least in part) for the
failure of steatotic livers to engraft [75] and to contribute to
NASH [76].
The case of IR injury
IR is a biphasic process entailing a massive necrotic and apoptotic
cell death response that is initiated at reperfusion, along with the
most often unsuccessful attempt of cells to re-establish homeo-
stasis via autophagy [77] Hepatic IR is a particularly interesting
model as its main pathological consequence, i.e., the massive loss
of hepatocytes during reperfusion, originates from a complex
crosstalk between ER stress, oxidative stress, and inﬂammation
during ischemia. Hypoxia induces indeed a considerable overgen-
eration of ROS [78], in turn (i) directly stimulating the (at least
partially) NF-jB-dependent transactivation of various pro-
inﬂammatory mediators [53] and (ii) promoting protein unfold-
ing and hence triggering the ER stress response (as documented
by the activation of XBP1 and ATF6 in the parenchyma of livers
undergoing IR) [44,45]. Interestingly, the hepatic ER stress
response per se exerts pro-inﬂammatory functions, both as it
allows for the activation of the pro-inﬂammatory hepatocyte-
speciﬁc transcription factor CREBH [79] and as it sensitizes
liver-resident macrophages to stimulation by Toll-like receptor
4 (TLR4) agonists as well as hepatocytes to cell death induction
by TNFa [44]. In line with this notion, mice pretreated with 4-
phenylbutyrate, a synthetic chaperone used as an ER stress inhib-
itor, were protected from hepatic IR while manifesting reduced
pro-inﬂammatory responses [80]. Moreover, ischemic pre-condi-
tioning has been associated with the upregulation of the IL-1
receptor antagonist IL-1RA, BCL-2 and NO [81], suggesting that
the hepatoprotective effects of this maneuver stem from the inhi-
bition of inﬂammation and cell death coupled to the activation of
repair mechanisms. Of note, TLR4 agonists, which generally oper-
ate as adjuvants to promote immune responses, have been shown
to reduce hepatic damage in steatotic livers maintained in UW
preservation solution [82], implying that TLR4 signaling not
always mediates hepatotoxic effects.
Taken together, these observations suggest that the hepato-
toxic effects of IR originate from a complex crosstalk between
hepatocytes, tissue-resident immune cells and immune cells that
are recruited to the site of injury. In this setting, a major role is
played by the ER stress response, by lipid signals and by dam-
age-associated molecular patterns (DAMPs) that are released by
dying hepatocytes, as discussed below.Lipids, major pleiotropic signals of inﬂammation and cell
death
Lipids constitute a structurally heterogeneous group of hydro-
phobic molecules that serve a wide variety of functions. Lipids
are indeed prominent energy-storing molecules (leading to a
much higher caloric yield, i.e., 9 kcal/g, than carbohydrates
and proteins, i.e., 4 kcal/g), critically contribute to the formation
of biological membranes, and participate in several signal trans-
duction cascades [83]. The liver plays a central role in the sys-
temic metabolism of lipids and several classes of lipids,
including (but not limited to) prostaglandins, leukotrienes, cera-
mides and fatty acids, have been shown to mediate hepatotoxic
effects while stimulating hepatic inﬂammation.Journal of Hepatology 201Prostaglandins
Cyclooxygenase 2 (COX2)-derived prostaglandins have been
implicated in diverse physiopathological processes including cell
proliferation and activation of inﬂammatory responses [84]. Most
non-steroidal anti-inﬂammatory drugs (NSAIDs), including block-
busters such as acetylsalicylic acid, ibuprofene and sulindac, de
facto operate as relatively unspeciﬁc COX inhibitors, blocking
the conversion of arachidonic acid into prostaglandins [84]. As
it stands, the implication of COX2 in hepatic diseases remains
controversial. On the one hand, indeed, the hepatocyte-speciﬁc
transgenic expression of COX2 has been shown to accelerate D-
galactosamine/LPS-induced liver failure by a prostaglandin E
(PGE) receptor 1, subtype EP1 (PTGER1)-dependent mechanism
involving the activation of JNK2 [85], and PGE2 has been causally
involved in NAFLD and NASH [86]. On the other hand, robust
genetic data indicate that COX2 protects mice from fatal hepatitis
as triggered by agonistic anti-FAS antibodies, presumably as it
regulates the expression of the epidermal growth factor receptor
(EGFR) [87]. Along similar lines, prostaglandins (and in particular
PGE2) appear to mediate robust hepatoprotective functions
against IR and acetaminophen hepatotoxicity [88,89].
Leukotrienes
Together with prostaglandins, leukotrienes, which are generated
by the catalytic activity of the enzyme arachidonate 5-lipoxyge-
nase (ALOX5), constitute the major products of arachidonic acid
metabolism [90]. Besides participating in inﬂammatory
responses, leukotrienes promote chemotaxis and regulate the
contraction of tracheal smooth muscles, contributing to the path-
ogenesis of asthma [91]. The knockout of Alox5 reportedly ame-
liorates the steatotic, inﬂammatory, and ﬁbrotic responses
spontaneously developing in Apoe-/- mice [92] or resulting from
the administration of CCl4 [93]. Along similar lines, chemical
inhibitors of ALOX5 or 5-lipoxygenase-activating protein (FLAP,
an ALOX5 interactor) have been shown to reduce CCl4-induced
liver injury [94] and to limit the inﬂammatory inﬁltration of
the hepatic parenchyma in several distinct models of NASH and
NAFLD [92], perhaps as they induce the preferential demise of
activated Kupffer cells. Similar to ALOX5, arachidonate 15-lipoxy-
genase, another enzyme involved in arachidonic acid metabolism,
may also play a prominent role in the pathogenesis of NASH and
NAFLD [95].
Ceramides
Ceramides are lipid messengers that accumulate in response to
various stress conditions, either upon the hydrolysis of sphingo-
myelin by sphingomyelinases or via a 3-step biosynthetic path-
way that mainly occurs at ER membranes [96]. Ceramides are
well known for their capacity to control proliferation and apopto-
sis at a cell-autonomous level [97] and are now emerging as
prominent regulators of systemic metabolism [96]. In particular,
ceramides, which also accumulate in response to death receptor
activation [98], promote direct mitochondriotoxic effects [99],
stimulate ROS generation [100], and inhibit various anti-apopto-
tic signal transducers, including AKT [101]. Mice lacking acidic
sphingomyelinase (aSMase) are signiﬁcantly protected against
the lethal hepatotoxic effects of D-galactosamine/LPS, TNFa and
agonistic anti-FAS antibodies [102,103]; and imipramine, a chem-3 vol. 59 j 583–594 587
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ical aSMase inhibitor, has been shown to limit hepatic damage
upon IR injury [104]. Along similar lines, myriocin, an inhibitor
of de novo ceramide synthesis, appears to reduce body weight,
enhances metabolism and ameliorates energy expenditure in
genetically obese (ob/ob) mice as well as in animals exposed to
a high-fat diet (HFD) [105]. Of note, myriocin has also been
reported to suppress hepatitis C virus replication (HCV) in vivo
[106], suggesting that ceramides may constitute central hepato-
toxic mediators in a wide variety of pathological settings.
Fatty acids and neutral fats
Fatty acids and neutral fats (including mono-, di-, and triglycer-
ides) constitute prominent energetic substrates, central compo-
nents of cell membranes and serve as precursors for the
synthesis of several other molecules [83]. Nevertheless, the accu-
mulation of fatty acids and neutral fats as a result of metabolic
disorders (e.g., insulin resistance, which is generally accompanied
by an increase in circulating fatty acids) or an unbalanced diet is
toxic for several tissues, including the liver [107]. In these set-
tings, as well as in response to various toxins and xenobiotics
including ethanol, fatty acids and neutral fats (mainly di- and tri-
glycerides) accumulate within hepatocytes, resulting in a peculiar
alteration of the hepatic parenchyma known as steatosis [107].
Irrespective of its origin, steatosis is associated with (at least
some extent) of hepatic damage, resulting from the pro-apoptotic
activity of free fatty acids (FFAs) and (hepatocyte death-related)
inﬂammation [108].
Results from recent studies involving leptin- (ob/ob) and lep-
tin receptor-deﬁcient (db/db) obese mice and multiple in vitro
models of lipotoxicity [109,110] suggest that the hepatotoxic
effects of FFAs are mediated in part by mitochondrial apoptosis
and in part by death receptor-transduced signals, but not by
RIPK1-dependent signal pathways. In particular, FFA-induced
apoptosis appears to involve the activation of the tumor suppres-
sor protein p53 [111], the overexpression of TRAIL receptors
[111], ROS overproduction [112], BAX-dependent lysosomal
membrane permeabilization [113], as well as direct mitochond-
riotoxic effects that result from the local accumulation of modi-
ﬁed lipids, such as oxidized cardiolipin [114] and ceramides
[115]. In line with this notion, a combination of saturated fatty
acids such as palmitic and oleic acid has been shown to sensitize
hepatocytes to cell death induction by various stimuli [9]. In ob/
ob mice, this manifests with morphological and structural altera-
tions of hepatocyte mitochondria as well as with reduced levels
of VDAC1 phosphorylation by glycogen synthase kinase 3b
(GSK-3b), increasing the propensity of these organelles to accu-
mulate Ca2+ ions and to undergo lethal MOMP [9]. This said,
the actual role of GSK-3b in lipotoxicity (i.e., whether it promotes
or inhibits FFA-induced cell death) remains to be clariﬁed, as con-
trasting observations have been reported in this respect [9,116].
The liver of HFD-fed mice is inﬁltrated by a consistent amount
of immature myeloid cells. Together with liver-resident Kupffer
cells [117], these CD11b+Ly6ChighLy6G cells secrete TH1 cyto-
kines such as IL-12 and interferon c (IFNc), hence facilitating
the activation-induced death of local natural killer T (NKT) cells
and initiating a vicious feedforward loop bridging inﬂammation
and HFD-associated hepatotoxicity [118]. The existence of a phys-
iopathologically relevant link between FAAs, apoptosis, and
inﬂammation has been validated by an immunohistochemical
study of hepatic biopsies from 84 NAFLD patients, demonstrating588 Journal of Hepatology 201that the stage of disease correlates with increased p53 expression
levels and decreased amounts of BCL-2 [119]. Taking this into
account, it would be an oversimpliﬁcation to consider all lipids
as equally hepatotoxic. Indeed, while the lipotoxic potential of
FFAs taken as a single class of lipids is established, (i) distinct FFAs
differ in their ability to promote cell death, saturated and long lip-
ids being generally viewed as more toxic than their non-saturated
and short counterparts [119]; and (ii) neutral fats (in particular
triglycerides) appear to be relatively inert, if not to activate an
adaptive response that exerts hepatoprotective effects [109,120].DAMPs, ampliﬁcation signals for inﬂammation and cell death
DAMPs, also called alarmins, constitute a group of chemically
heterogeneous molecules that are exposed/released by dying
cells to operate as modulators (most often activators) of sterile
inﬂammation [121] (Table 1). Of note, in physiological conditions,
DAMPs serve ‘‘daily jobs’’, i.e., they contribute to inﬂammation-
unrelated cellular functions, in thus far resembling several com-
ponents of the cell death machinery [122].
To date, molecules as diverse as nuclear and mitochondrial
DNA [123–126], purine nucleotides (i.e., ATP, UTP) [127,128], uric
acid [129,130], lipids (i.e., sphingosine-1-phosphate [SP1]) [131],
nuclear factors (i.e., high-mobility group box 1 [HMGB1], IL-33)
[124,132,133], mitochondrial N-formyl peptides [121,126], ER
chaperones (i.e., CRT, ERp57, GP96) [47,48], heat-shock proteins
(HSPs, e.g., HSPA1A, HSP90AA1) [48,134–136] cytoskeletal pro-
teins (i.e., F-actin) [137] and S100 proteins [138] have been found
to behave as DAMPs. In spite of such a structural and chemical
heterogeneity, DAMPs share the property of being concealed
from the microenvironment in physiological conditions and of
being exposed and/or released in response to cellular damage
[139]. Until recently, necrotic cells were considered as the most
prominent, if not the only, source of DAMPs [139]. At least in part,
this notion stemmed from the facts that the plasma membrane
remains intact throughout apoptosis and that apoptotic corpses
are normally cleared by phagocytes before secondary necrosis
intervenes (and hence before their content can passively spill into
the extracellular microenvironment), owing to the exposure of
speciﬁc eat-me signals such as phosphatidylserine [140]. How-
ever, it is now clear that apoptosis can also be associated with
the exposure/release of several DAMPs and hence can activate
inﬂammatory or immune responses [46].
Interestingly, DAMPs may not always operate as pro-inﬂam-
matory mediators. For instance, IL-33, a cytokine that in healthy
cells mainly functions as a transcription factor [133], appears to
inhibit, rather than stimulate, inﬂammatory reactions elicited
by dying cells, perhaps owing to its capacity of preferentially acti-
vating TH2 immune responses [141]. Moreover, the binding of
generally pro-inﬂammatory DAMPs, such as HMGB1 and HSPs,
to ‘‘alternative’’ receptors, such as CD24 or SIGLEC10, sialic
acid-binding Ig-like lectin 10 (SIGLEC10), has been reported to
mediate consistent anti-inﬂammatory effects [134].
The implication of speciﬁc DAMPs and cognate pattern recog-
nition receptors (PRRs) in the pathogenesis of liver diseases has
just begun to emerge. Thus, hepatocytes have been shown to
secrete ATP, most likely via pannexin 1 channels, as they suc-
cumb to FFAs [142] and acetaminophen [143], promoting the
P2Y2-dependent inﬁltration of neutrophils and hence aggravat-
ing hepatic damage [143]. The non-histone chromatin-binding3 vol. 59 j 583–594
Table 1. Examples of DAMPs potentially involved in liver disease.
DAMP Function(s) Receptor(s) Emission pathway Notes Ref.
ATP
UTP
Purine metabolites
NLRP3 inflammasome 
activators
P2RX7
P2Y2
Secreted via autophagy- 
and PANX1-dependent 
mechanisms
Involved in the pathogenesis of 
conA-induced acute liver injury
[127, 128, 
143]
CRT
ERp57
ER chaperones
Eat-me signals
CD91 Exposed upon ER stress via 
the Golgi secretory pathway
ER stress plays a causative role 
in several hepatic disorders
[46, 47]
F-actin Cytoskeletal component 
DC recruitment
CLEC9a Exposed upon PMP Not yet formally involved 
in liver disease
[137]
HMGB1 Multifunctional 
nuclear factor
Adjuvant
Anti-inflammatory 
function (?)
AGER
TLR4
CD24/
SIGLEC10
Released upon 
NMP and PMP
Involved in the pathogenesis 
of acute liver failure, 
hepatic IR and HBV infection
[134, 145-
149]
HSPs Molecular chaperons
Adjuvants
Anti-inflammatory
function (?)
TLR2
TLR4
Released upon PMP 
or secreted via active, 
exosome-dependent routes
Implicated in the response 
to hepatic IR and other 
hepatotoxic conditions
[48, 134-136]
IL-33 Repressor of nuclear 
transcription
Anti-inflammatory factor
IL1RL1 Released upon 
NMP and PMP
Released during acute and
chronic liver failure, hepatic 
IR and conA intoxication
[133, 158, 
159]
mtDNA Gene expression
Adjuvant
NLRP3 inflammasome 
activation
NLRP3
TLR9
Released upon mitochondrial 
damage and PMP
mtDNA can be detected 
in the circulation of patients 
undergoing acute liver failure
[125, 126, 
151, 152]
nDNA Gene expression
Adjuvant
NLRP3 inflammasome 
activator
Pro-fibrotic molecule
NLRP3
TLR9
Released upon 
NMP and PMP
Implicated in the fibrotic 
response to acetaminophen
[123, 124, 
150]
N-formyl 
peptides
Mitochondrial polypeptides
Potent neutrophil 
activators
FPR1 Released upon mitochondrial 
damage and PMP
N-formyl peptides can be 
detected in the blood of patients 
undergoing acute liver failure
[121, 126, 
152]
S100 
proteins
Pleiotropic roles
Adjuvants
AGER
TLR4
Secreted via conventional 
secretory pathways or 
released upon PMP
Not yet formally involved 
in liver disease, participate in 
hepatocellular carcinogenesis
[138]
S1P Lipid
Anti-apoptotic stimulus
Come and get me-signal
S1PR Secreted via a carrier-
dependent mechanism or 
released upon PMP
Implicated in the pathogenesis
of post-transplantation and conA-
triggered hepatic damage
[153, 154]
Uric acid Purine catabolite
Pro-inflammatory 
metabolite
NLRP3 Released upon PMP Implicated in acetaminophen 
hepatotoxicity
[129, 130]
AGER, advanced glycosylation end product-speciﬁc receptor; conA, concanavalin A; CRT, calreticulin; DAMP, damage-associated molecular pattern; ER, endoplasmic
reticulum; FPR1, formyl peptide receptor 1; HBV, hepatitis B virus; HMGB1, high mobility group box 1; HSP, heat-shock protein; IL, interleukin; ILRL1, IL receptor-like 1; IR,
ischemia reperfusion; mtDNA, mitochondrial DNA; nDNA nuclear DNA; NLRP3, NOD-like receptor family, pyrin domain containing 3; NMP, nuclear membrane perme-
abilization; PANX1, pannexin 1; PMP; plasma membrane permeabilization; S1P, sphingosine-1-phosphate; S1PR, S1P receptor; SIGLEC10, sialic acid-binding Ig-like lectin
10; TLR, Toll-like receptor.
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patients undergoing acute liver failure [144,145] as well as in
rodent models of hepatic IR [146,147], hepatitis B virus (HBV)
infection [148] and concavalin A intoxication [145,149], de facto
playing a major etiological role in these settings (as demon-
strated by pharmacological and genetic experiments). Upon bind-
ing to TLR9, nuclear DNA released by acetaminophen-exposed
hepatocytes promotes the differentiation of hepatic stellate cells
(HSCs), hence favoring the secretion of collagen and other ﬁbro-
sis-associated factors [150], as well as the production of pro-
inﬂammatory cytokines such as IL-1b and IL-18 by tissue-resi-
dent and freshly recruited immune cells [151]. The circulating
levels of mitochondrial DNA and N-formyl peptides, both of
which are reminiscent of the endosymbiotic origin of these
organelles, are elevated in patients undergoing acute liver failureJournal of Hepatology 201[152]. Moreover, Tlr9/ deﬁcient mice as well as animals receiv-
ing a blocking anti-formyl peptide receptor 1 (FPR1) antibody are
protected against acetaminophen-induced liver injury [152]. In
rats, the inhibition of sphingosine kinase 2, one of the enzymes
that generate the pro-inﬂammatory ceramide derivative S1P
[131], has been shown to suppress inﬂammation and to attenuate
hepatic damage upon transplantation [153]. Conversely, chemical
agonists of the S1P receptor reportedly protect mice from conca-
navalin A hepatotoxicity [154]. Along similar lines, several poten-
tially immunogenic HSPs, such as HSPA1A and HSPB1 [135,136],
have been implicated in the hepatic response to IR and other hep-
atotoxic challenges, yet the major role of these proteins in this
context seems to relate to their capacity to exert cytoprotective
effects by operating as intracellular chaperones [155,156]. Fur-
thermore, the circulating levels of IL-33 are elevated in patients3 vol. 59 j 583–594 589
Fig. 3. Damage-associated molecular patterns link inﬂammation to cell death
in the liver. (A) Upon exposure to most, if not all, hepatotoxic conditions,
hepatocytes as well as liver-resident immune cells (e.g., Kupffer cells, natural
killer [NK] cells; natural killer T [NKT] cells) activate adaptive responses including
autophagy, in an attempt to cope with stress. This generally results in mild
inﬂammation coupled to the recruitment and local differentiation of circulating
immune cells (mainly monocytes), contributing to the re-establishment of
homeostasis. (B) When such adaptive responses fail, however, stressed hepato-
cytes undergo apoptosis or necrosis, resulting in the massive release of damage-
associated molecular patterns (DAMPs) into the extracellular microenvironment.
By binding to speciﬁc pattern-recognition receptors expressed by liver-resident
and freshly recruited immune cells, DAMPs exert potent immunomodulatory
(most often immunostimulatory) functions, hence aggravating the ongoing
inﬂammatory response. In this setting, immune cells are stimulated to secrete a
wide panel of pro-inﬂammatory and hepatotoxic factors, leading to a vicious
cycle connecting inﬂammation and cell death that mediates severe hepatotoxic
effects. DC, dendritic cell.
Reviewwith acute or chronic liver failure [157], and IL-33 is released by
the hepatocytes of mice exposed to hepatic IR [158] or treated
with concavalin A [159], yet appears to mediate anti-inﬂamma-
tory, rather than pro-inﬂammatory, effects.
Taken together, these observations indicate that DAMPs often
constitute major etiological determinants of hepatic diseases as
they control, most often stimulating, a vicious cycle bridging cell
death and inﬂammation in the liver (Fig. 3).Endogenous control of inﬂammation
Besides the removal of apoptotic corpses and necrotic cells by
phagocytes, which limits inﬂammation as it reduces the availabil-
ity of DAMPs [160], two additional mechanisms have been shown
to operate an endogenous control over hepatic inﬂammation,
namely, cellular senescence and autophagy.
Senescence control
The accumulation of senescent HSCs is one of the hallmarks of
some forms of ﬁbrotic liver injury [161]. In response to inﬂamma-590 Journal of Hepatology 201tory stimuli, HSCs proliferate in response to TLR4-mediated sig-
nals and to TGFb produced by Kupffer cells [162]. However, as
chronic inﬂammation fails to resolve, HSCs progressively acquire
a senescent phenotype, hence manifesting a permanent cell cycle
arrest as well as an increased secretion of speciﬁc cytokines (e.g.,
IL-6, IL-8, IL-11) and extracellular matrix-degrading enzymes
[161]. Moreover, the expression of high levels of natural killer
(NK)-cell activating receptor ligands (e.g., MICA, ULBP2, PVR) on
the surface of senescent HSCs for allows their elimination by tis-
sue-resident NK cells, an immunosurveillance mechanism that
contributes to the resolution of ﬁbrosis [161].
Although this pathway associating hepatic ﬁbrosis, senescence,
and immunosurveillance has been primarily described in a model
of acute liver intoxication, the immune system may similarly be
involved in the development of severe or chronic liver pathologies
such as cirrhosis and hepatocellular carcinoma, especially in the
context of immunosuppressed and/or aged patients [163].Autophagic control
In hepatocytes, autophagy contributes to the removal of dam-
aged (and hence potentially toxic) mitochondria [33] as well as
to the control of the intracellular lipidome [164]. The selective
autophagic degradation of mitochondria (also known as mito-
phagy) can be initiated by MOMP and often involves a well char-
acterized signal transduction pathway centered on the
interaction between parkin and PTEN-induced putative kinase
1 (PINK1), two proteins that are mutated in familial Parkinson’s
disease [33]. By preserving the functional pool of mitochondria,
autophagy minimizes ROS generation, hence quenching the acti-
vation of intracellular pro-inﬂammatory factors including the
NLRP3 inﬂammasome and NF-jB [165]. Along similar lines,
autophagy is required for the normal intracellular metabolism
of lipids, as autophagic defects are associated with an increased
accumulation of triglycerides, in vitro and in vivo [164]. Both
these functions of autophagy are particularly important in the
liver, as various hepatic disorders (i) are accompanied by mito-
chondrial dysfunction and ROS overproduction [112], and/or
(ii) are associated with the accumulation of lipids in the hepatic
parenchyma [109,115]. In addition, autophagy has recently been
shown to inhibit the release of mitochondrial DNA by cardio-
myocytes in vivo, thus limiting the activation of the NLRP3
inﬂammasome and the pathological consequence of pressure
overload [125]. Furthermore, HMGB1 appears to stimulate
autophagy (while inhibiting cell death) upon binding to
advanced glycosylation end product-speciﬁc receptor (AGER,
best known as RAGE) on the surface of pancreatic tumor cells
[166]. It remains to be determined whether similar processes
also occur in the liver.Conclusions and perspectives
The incidence of hepatic pathologies in developed countries is
constantly increasing owing to multiple lifestyle factors (e.g.,
excessive caloric intake, unbalanced diet, lack of physical exer-
cise, abuse of hepatotoxic drugs) coupled to an augmented life
expectancy. Given the central role of cell death and inﬂammation
in the etiology of most, if not all, liver disorders, one valid thera-
peutic strategy may involve the use of hepatoprotective and anti-
inﬂammatory interventions, either alone or combined. Clinical3 vol. 59 j 583–594
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trials are currently underway to test this hypothesis in cohorts of
patients affected by a wide variety of hepatic conditions (source
www.clinicaltrials.gov).
Recently, DAMPs and the corresponding PRRs have attracted
great attention as candidate targets for the therapy of acute
inﬂammatory disorders such as the systemic inﬂammatory
response syndrome (SIRS) [17,126], but their prominent role in
hepatic disorders has just begun to emerge. We surmise that
the precise characterization of the molecular mechanisms and
cellular actors whereby speciﬁc DAMPs modulate hepatic inﬂam-
matory responses will lead to the development of novel and
effective hepatoprotective measures.Conﬂict of interest
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